第6章 競爭評估

第7章 未滿足需求和機會

第8章 開發平台評估

第9章 現在、未來的主要企業

第10章 市場預測

全球市場

美國

EU5個國家

日本

巴西

中國

第11章 附錄

圖表

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Product Code: GDHC135PIDR

Global HIV therapeutics market was worth approximately US$16.3 billion in 2015, and GlobalData projects this market to reach a total of US$22.5 billion in sales by 2025, at a Compound Annual Growth Rate (CAGR) of 3.3%.

Human immunodeficiency virus (HIV) is a retrovirus that infects the cells of the immune system, destroying or impairing their function. As the infection progresses, the immune system becomes increasingly weaker, making the infected person more susceptible to other infections. Since the first anti-HIV drug, GlaxoSmithKline's (GSK's) Retrovir (azidothymidine), was approved in 1987, major improvements have been made in the field of antiretroviral therapy (ART).

Some of the main drivers of the growth of the HIV market during the forecast period are expected to be -

An increasing number of people living with HIV who are treated with antiretroviral therapy (ART).

Increased efforts to identify new HIV infections through more aggressive screening and diagnostic policies, along with new and more sensitive diagnostic testing tools and methods.

Adoption of the test-and-treat approach to increase the number of patients on ART and reduce viral loads.

HIV market is dominated by the Big Pharma players, such as Gilead, ViiV Healthcare (a collaboration between GlaxoSmithKline [GSK], Pfizer, and Shionogi), Janssen, and Merck, and other companies that have carved out a niche in the existing marketplace. While some of the companies involved in the HIV marketplace have invested in their R&D to build exhaustive pipelines spanning all phases of clinical development, others, such as Bristol-Myers Squibb (BMS), moved out of the HIV market in favor of other disease markets, such as oncology.

Two of the most important persistent unmet needs with regard to the current HIV therapies are concerns about drug adverse effects and the need for drugs that are active against drug-resistant strains of HIV. Currently, it is relatively common for drug-resistant viral strains to force physicians to move patients from one therapy to the next, which can result in in the emergence of untreatable strains and restrict the use of the available drugs. This is especially a concern among patients who are treated with a multi-pill regimen, which negatively affects compliance rates.

Analysis of the current and future market competition in the global HIV therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Analysis of the current and future market competition in the global HIV therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global HIV therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the HIV therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.